Leukemia

Articles

According to a single-institution study of patients with a known or suspected diagnosis of AML or MDS, whole-genome sequencing may provide better predictive ability of patients’ risk status than traditional methods.

Whole-Genome Sequencing May Improve Prognosis Accuracy for AML/MDS Versus Traditional Cytogenetics

Treatment with gilteritinib, compared with salvage chemotherapy, improved overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to a planned interim analysis of a phase 3 trial.

Confirmatory Trial of Gilteritinib Meets Primary End Point of Improving OS in Relapsed/Refractory FLT3+ AML

The FDA approved a revised label for daunorubicin/cytarabine to treat newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 and older.

FDA Approves Expanded Indication of Daunorubicin/Cytarabine to Include Children With AML

GT Biopharma announced updated data focusing on its therapeutic candidate, GTB-3550, to treat certain patients with myelodysplastic syndromes and acute myeloid leukemia.

Updated Data Provided From Phase 1/2 Trial Investigating GTB-3550 in Patients With MDS and AML

“As the first AML trial to use MRD negative CR as a primary endpoint, our trial is breaking new ground that may help deliver effective, targeted therapies more expeditiously to patients living with this devastating disease,” Bischofberger said.

Phase 3 Trial Initiated for Entospletinib in Patients With NPM1-mutated AML After Positive FDA Meeting

“The [phase 1b/2] data [are] promising and support the current phase 3, multicenter trial, which we hope will lead to FDA approval and a new much-needed treatment option for this patient population,” said David Sallman, MD.

Combination Treatment With Eprenetapopt and Azacitidine Shows Promise for TP53-Mutant MDS and AML

Data published in Cancer Discovery determined Black patients with acute myeloid leukemia have considerably worse overall survival rates than White patients with the same disease.

Younger Non-Hispanic Black Patients With AML Have Worse Overall Survival Rates Than White Patients

These data are the first to demonstrate that JSP191 is safe and effective in in older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation for MRD-positive acute myeloid leukemia or myelodysplastic syndrome.

JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS

Based on the results of an analysis, investigators suggested that if high-dose daunorubicin and cytarabine is the selected consolidation treatment for younger patients with acute myeloid leukemia, a fourth course of therapy is likely beneficial for most.

Optimal Number of Treatment Courses Explored in Younger Patients with AML

Data published in JAMA Oncology found boosts in quality of life in addition to improvements in depression, anxiety, and posttraumatic stress symptoms for patients with acute myeloid leukemia receiving integrated palliative and oncology care.

Acute Myeloid Leukemia | Topics